CTS-Clinical and Translational Science

Article	Citations
Precision Medicine, AI, and the Future of Personalized Health Care	335
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear	230
Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID‐19	220
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects	171
COVID‐19 and Immunological Dysregulation: Can Autoantibodies be Useful?	113
SARS‐CoV‐2 infection as a trigger of autoimmune response	93
The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID‐19 Patients: A Retrospective Cohort Study	87
Evolving Role for Pharmacotherapy in NAFLD/NASH	81
3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration	74
What Do We Know About Remdesivir Drug Interactions?	67
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19	61
Opportunities and challenges in translational science	55
Clinical Trial Generalizability Assessment in the Big Data Era: A Review	51
Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation	45
COVID‐19 and Venous Thromboembolism in Intensive Care or Medical Ward	44
Remote Monitoring in Clinical Trials During the COVID‐19 Pandemic	44
Pharmacogenomics Biomarker Discovery and Validation for Translation in Clinical Practice	41
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	41
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial	41
Risk Assessment of Drug‐Induced Long QT Syndrome for Some COVID‐19 Repurposed Drugs	38
Pharmacogenomics in Asian Subpopulations and Impacts on Commonly Prescribed Medications	38
An Evaluation of Biometric Monitoring Technologies for Vital Signs in the Era of COVID‐19	38
Risk of Metformin in Patients With Type 2 Diabetes With COVID‐19: A Preliminary Retrospective Report	38
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	36
Approval success rates of drug candidates based on target, action, modality, application, and their combinations	35

CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System	34
Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID‐19	34
Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto’s thyroiditis: A prospective randomized‐controlled trial	33
CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants	32
Hydroxychloroquine for Treatment of SARS‐CoV‐2 Infection? Improving Our Confidence in a Model‐Based Approach to Dose Selection	31
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID‐19: An Open‐Label Randomized Controlled Pilot Study	31
hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects	30
A Single and Multiple Ascending Dose Study of Toll‐Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers	30
A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study	30
Digitally Enabled, Patient‐Centric Clinical Trials: Shifting the Drug Development Paradigm	29
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	28
Human Induced Pluripotent Stem Cell Derived Sensory Neurons are Sensitive to the Neurotoxic Effects of Paclitaxel	27
Association Between Prescribed Ibuprofen and Severe COVID‐19 Infection: A Nationwide Register‐Based Cohort Study	26
Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers	25
Fit‐for‐Purpose Biometric Monitoring Technologies: Leveraging the Laboratory Biomarker Experience	25
Effect of SLCO1B1 Polymorphisms on High‐Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma	25
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)	25
Gene therapy for diabetic peripheral neuropathy: A randomized, placebo‐controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor	25
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events	24
The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19	24
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction	23
Drugs used for the treatment of cerebral and disseminated infections caused by free‐living amoebae	23
A Phase I Study of Dinaciclib in Combination With MK‐2206 in Patients With Advanced Pancreatic Cancer	23
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH	23
Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults	22
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off‐label in the first wave of COVID‐19	22
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19	22
Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo‐Controlled, Phase II Trial	21
Effect of Common Medications on the Expression of SARS‐CoV‐2 Entry Receptors in Kidney Tissue	21
First Clinical Study with AP30663 ‐ a KCa2 Channel Inhibitor in Development for Conversion of Atrial Fibrillation	20
The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence	20
Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study	20
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	20
Population Pharmacokinetics of Remimazolam in Procedural Sedation With Nonhomogeneously Mixed Arterial and Venous Concentrations	20
Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy	19
Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV	19
Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial	19
Artificial intelligence in pharmacology research and practice	19
Exocrine Pancreatic Dysfunction Increases the Risk of New‐Onset Diabetes Mellitus: Results of a Nationwide Cohort Study	18
Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double‐blind, placebo‐controlled trial	18
Febuxostat, But Not Allopurinol, Markedly Raises the Plasma Concentrations of the Breast Cancer Resistance Protein Substrate Rosuvastatin	18
Antinuclear antibodies in COVID 19	18
Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database	17
Effects of Bardoxolone Methyl on Hepatic Enzymes in Patients with Type 2 Diabetes Mellitus and Stage 4 CKD	17
Substantially Increased Plasma Coproporphyrin‐I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population	17
Characterizing Pharmacogenetic Testing Among Children’s Hospitals	17
Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study	17
Reimagining the peer‐review system for translational health science journals	16
Artificial intelligence in clinical and translational science: Successes, challenges and opportunities	16
Altered vitamin A metabolism in human liver slices corresponds to fibrogenesis	16

First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	16
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease	16
Development and Analytical Validation of a 29 Gene Clinical Pharmacogenetic Genotyping Panel: Multi‐Ethnic Allele and Copy Number Variant Detection	16
Upadacitinib pharmacokinetics and exposure‐response analyses of efficacy and safety in psoriatic arthritis patients – Analyses of phase III clinical trials	16
Enhanced Characterization of Drug Metabolism and the Influence of the Intestinal Microbiome: A Pharmacokinetic, Microbiome, and Untargeted Metabolomics Study	16
Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers	15
DNA Methylation‐Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia	15
Remote FEV1 Monitoring in Asthma Patients: A Pilot Study	15
Progress toward a universal biomedical data translator	15
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP‐458) in Healthy Adult Volunteers	15
Inter‐ and Intrafamilial Phenotypic Variability in Individuals with Collagen‐Related Osteogenesis Imperfecta	15
GSTP1andABCB1Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel‐Based Chemotherapy in Ovarian Cancer	14
Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults	14
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	14
Autoantibodies in moderate and critical cases of COVID‐19	14
Rivaroxaban Precision Dosing Strategy for Real‐World Atrial Fibrillation Patients	14
Insights on the Evidence of Cardiotoxicity of Hydroxychloroquine Prior and During COVID‐19 Epidemic	14
Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer	14
Remote Digital Monitoring for Medical Product Development	14
Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis	14
Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial	14
Metformin Preconditioning and Postconditioning to Reduce Ischemia Reperfusion Injury in an Isolated Ex Vivo Rat and Porcine Kidney Normothermic Machine Perfusion Model	14
Retrospective Review of Pharmacogenetic Testing at an Academic Children’s Hospital	14
Open Data Revolution in Clinical Research: Opportunities and Challenges	14
Improving the Pharmacodynamics and In Vivo Activity of ENPP1‐Fc Through Protein and Glycosylation Engineering	14
A call to action: Issuing a diversity and inclusion challenge to research organizations	14
Genistein‐Calcitriol Mitigates Hyperosmotic Stress‐Induced TonEBP, CFTR Dysfunction, VDR Degradation and Inflammation in Dry Eye Disease	13
Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study	13
A population pharmacodynamic Markov mixed‐effects model for determining remimazolam‐induced sedation when co‐administered with fentanyl in procedural sedation	13
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	13
A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework	13
Microphysiological systems in absorption, distribution, metabolism, and elimination sciences	13
Evaluation of the abuse potential of difelikefalin, a selective kappa‐opioid receptor agonist, in recreational polydrug users	13
Hypomethylation of NLRP3 gene promoter discriminates glucocorticoid‐resistant from glucocorticoid‐sensitive idiopathic nephrotic syndrome patients	13
Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic	13
Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity	13
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies	12
Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia	12
The vaccine hesitancy continuum among hesitant adopters of the COVID‐19 vaccine	12
Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2)	12
Impact of SLCO1B1 Genetic Variation on Rosuvastatin Systemic Exposure in Pediatric Hypercholesterolemia	12
Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials	12
Short‐ and long‐term effects of body weight loss following calorie restriction and gastric bypass on CYP3A‐activity – a non‐randomized three‐armed controlled trial	12
Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics	12
Pharmacokinetics of bempedoic acid in patients with renal impairment	12
Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population	12
A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab	12
Identification of small molecules that mitigate vincristine‐induced neurotoxicity while sensitizing leukemia cells to vincristine	12
Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19	12
Effect of meal timing on pharmacokinetics and pharmacodynamics of tegoprazan in healthy male volunteers	12
Correlation Analysis Among the Level of IL‐35, Microvessel Density, Lymphatic Vessel Density, and Prognosis in Non‐Small Cell Lung Cancer	12
Genetic Diversity in Drug Transporters: Impact in African Populations	12
Diagnostic and prognostic capabilities of a biomarker and EMR‐based machine learning algorithm for sepsis	12
Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities	12
Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically‐Based Pharmacokinetic Modeling	11
G970R‐CFTR Mutation (c.2908G>C) Results Predominantly in a Splicing Defect	11
SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma	11
A Simple and Rapid UPLC‐UV Method for Detecting DPD Deficiency in Patients With Cancer	11
MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Dependent mTOR Pathway	11
Preoperative medication use and development of postoperative delirium and cognitive dysfunction	11
Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2	11
Evolving drug regulatory landscape in China: A clinical pharmacology perspective	11
Pharmacokinetic equivalence of CT‐P17 to high‐concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects	11
Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT‐P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study	11
A phase I evaluation of the effect of curcumin on dose‐limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors	11
First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects	11
Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy	11
US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer’s Disease: Implications for Global Drug Development	11
PF‐07321332 (Nirmatrelvir) does not interact with human ENT1 or ENT2: Implications for COVID‐19 patients	11
Clinical Pharmacology Studies Supporting Oligonucleotide Therapy Development: An Assessment of Therapies Approved and in Development Between 2012 and 2018	11
Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)	11
Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs	11
Compassionate use of ruxolitinib in patients with SARS‐Cov‐2 infection not on mechanical ventilation: Short‐term effects on inflammation and ventilation	11
Perioperative Dexmedetomidine Improves Outcomes of Kidney Transplant	11
Therapeutic Potential of Mesenchymal Stem Cells for Postmastectomy Lymphedema: A Literature Review	11
In vitro safety “clinical trial” of the cardiac liability of drug polytherapy	11
Effects on the Ocular Surface from Reading on Different Smartphone Screens: A Prospective Randomized Controlled Study	10
Optimizing COVID‐19 Candidate Therapeutics: Thinking Without Borders	10
Advancing translational science education	10
Pediatric Pharmacokinetics and Dose Predictions: A Report of a Satellite Meeting to the 10th Juvenile Toxicity Symposium	10

Annual Bleeding Rates: Pitfalls of Clinical Trial Outcomes in Hemophilia Patients	10
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	10
Serum Metabolomic Profiles Associated With Untreated Metabolic Syndrome Patients in the Chinese Population	10
Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease	10
Effect of cenobamate on the single‐dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects	10
Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies	10
REGN1908‐1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: Translational pharmacokinetics and pharmacodynamics	10
Effects of vancomycin‐induced gut microbiome alteration on the pharmacodynamics of metformin in healthy male subjects	10
Evaluation of moxifloxacin in canine and non‐human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration‐QTc analysis	10
Effect of Crohn’s Disease on Villous Length and CYP3A4 Expression in the Pediatric Small Intestine	10
Effects of 5‐HT₃ receptor antagonists on cisplatin‐induced kidney injury	10
HLA‐associated adverse drug reactions ‐ scoping review	10
Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID‐19	9
Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N‐dimethyltryptamine – Implications for dose considerations	9
Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions	9
Predictors of Adverse Events and Determinants of the Voriconazole Trough Concentration in Kidney Transplantation Recipients	9
Pharmacometabolomics identifies candidate predictor metabolites of an L‐carnitine treatment mortality benefit in septic shock	9
Quantitative protein expression of blood‐brain barrier transporters in the vasculature of brain metastases of patients with lung and breast cancer	9
Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐Guided First‐in‐Human Studies	9
Sarcopenia in Patients With Normal Body Mass Index Is an Independent Predictor for Postoperative Complication and Long‐Term Survival in Gastric Cancer	9
Design and conduct considerations for studies in patients with impaired renal function	9
Potential Protective Effects of the Water‐Soluble Chinese Propolis on Hypertension Induced by High‐Salt Intake	9
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease	9
Asia‐inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial	9
Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clini	9
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator	9
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria	9
Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects	9
Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS‐441524 in patients with COVID‐19: A limited case series	9
Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients	9
The economics of moonshots: Value in rare disease drug development	9
Persistent follicular granulosa cell senescence and apoptosis induced by methotrexate leading to oocyte dysfunction and aberrant embryo development	9
Projected Utility of Pharmacogenomic Testing Among Individuals Hospitalized With COVID‐19: A Retrospective Multicenter Study in the United States	9
Real‐world evidence of population differences in allopurinol‐related severe cutaneous adverse reactions in East Asians: A population‐based cohort study	9
Pharmacokinetic equations versus Bayesian guided vancomycin monitoring: Pharmacokinetic model and model‐informed precision dosing trial simulations	9
Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab	9
Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development	9
Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies	9
Predicting citation impact from altmetric attention in clinical and translational research: Do big splashes lead to ripple effects?	9
Facilitators and barriers to pediatric clinical trial recruitment and retention in rural and community settings: A scoping review of the literature	9
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment	9
A metabolomic analysis of thiol response for standard and modified N‐acetyl cysteine treatment regimens in patients with acetaminophen overdose	8
Is this the end for ranitidine? NDMA presence continues to confound	8
Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat	8
Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel	8
A Practice‐Based, Clinical Pharmacokinetic Study to Inform Levetiracetam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemofiltration (PADRE‐01)	8
Type‐2 airway inflammation in mild asthma patients with high blood eosinophils and high fractional exhaled nitric oxide	8
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics	8
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	8
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling	8
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2	8
Estimation of glomerular filtration rate for drug dosing in patients with very high or low body mass index	8
Prediction of Survival Benefit of Filgrastim in Adult and Pediatric Patients With Acute Radiation Syndrome	8
Metabolomics analysis of the serum from children with urolithiasis using UPLC‐MS	8
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes	8
Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat	8
Fear and food: Anxiety‐like behavior and the susceptibility to weight loss in an activity‐based anorexia rat model	8
Proton pump inhibitor use and risk of depression and anxiety in children: nationwide cohort study	8
Potential benefit of vitamin D supplementation in people with respiratory illnesses, during the COVID‐19 pandemic	8
Adherence to triple‐component antihypertensive regimens is higher with single‐pill than equivalent two‐pill regimens: A randomized controlled trial	8
DDGP vs. SMILE in Relapsed/Refractory Extranodal Natural Killer/T‐cell Lymphoma, Nasal Type: A Retrospective Study of 54 Patients	8
Clinical differences in sirolimus treatment with low target levels between children and adults with vascular malformations – A nationwide trial	8
A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults	8
Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID‐19: A simulation study	8
Adverse event profiles of epidermal growth factor receptor‐tyrosine kinase inhibitors in cancer patients: A systematic review and meta‐analysis	8
Assessing the impact of COVID‐19 on registered interventional clinical trials	8
Population pharmacokinetic and exposure‐response analyses of ivosidenib in patients with IDH1‐mutant advanced hematologic malignancies	8
Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity	8
Efficacy of personal pharmacogenomic testing as an educational tool in the pharmacy curriculum: A nonblinded, randomized controlled trial	8
Impact of Green Tea Catechin Ingestion on the Pharmacokinetics of Lisinopril in Healthy Volunteers	8
Performance of Plasma Adenosine as a Biomarker for Predicting Cardiovascular Risk	8
Effect of inhaled corticosteroids on microbiome and microbial correlations in asthma over a 9‐month period	8
Early M‐Protein Dynamics Predicts Progression‐Free Survival in Patients With Relapsed/Refractory Multiple Myeloma	7
An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma	7
Practical publication metrics for academics	7
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development	7
Atorvastatin population pharmacokinetics in a real‐life setting: Influence of genetic polymorphisms and association with clinical response	7
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers	7
Recommended practices and ethical considerations for natural language processing‐assisted observational research: A scoping review	7
Genetics of drug‐induced liver injury: Current knowledge and future prospects	7
Reduction of Renal Preservation/Reperfusion Injury by Controlled Hyperthermia During Ex Vivo Machine Perfusion	7
Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants	7
Translational and pharmacokinetic‐pharmacodynamic application for the clinical development of GDC‐0334, a novel TRPA1 inhibitor	7
Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation	7
Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis	7
Risk Factors for Bleeding and Clinical Ineffectiveness Associated With Clopidogrel Therapy: A Comprehensive Meta‐Analysis	7
Pharmacokinetics, pharmacodynamics, safety and tolerability of cilofexor, a novel nonsteroidal Farnesoid X receptor agonist, in healthy volunteers	7
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	7
Multi‐site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos	7
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	7
Beyond the Michaelis‐Menten: Accurate Prediction of In Vivo Hepatic Clearance for Drugs With Low KM	7
Systemic Lupus Erythematosus Activity Affects the Sinusoidal Uptake Transporter OATP1B1 Evaluated by the Pharmacokinetics of Atorvastatin	7
Systems‐based digital twins to help characterize clinical dose–response and propose predictive biomarkers in a Phase I study of bispecific antibody, mosunetuzumab, in NHL	7
Estimating peptide half‐life in serum from tunable, sequence‐related physicochemical properties	7
Approach to High Volume Enrollment in Clinical Research: Experiences from an All of Us Research Program Site	7